2021 annual financial data
CRISPR Therapeutics 2021 Operating cash flow margin
Direct answer
Operating cash flow margin was 59.03%.
Operating income was 373,528,000 USD and net income was 377,661,000 USD.
Operating cash flow was 538,972,000 USD.
Get free CRISPR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 913,081,000 USD
- Operating income
- 373,528,000 USD
- Net income
- 377,661,000 USD
- Operating cash flow
- 538,972,000 USD